A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills.
Source link : https://www.nytimes.com/2025/01/15/us/340b-apexus-drugs-middleman.html
Author : Ellen Gabler
Publish date : 2025-01-15 15:15:00
Copyright for syndicated content belongs to the linked Source.